Advertisement


Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL

2014 ASH Annual Meeting

Advertisement

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794, “Inotuzumab Ozogamicin in Combination With Low-Intensity Chemotherapy (Mini-Hyper-CVD) as Front-Line Therapy for Older Patients (≥ 60 years) With Acute Lymphoblastic Leukemia,” presented by Elias Jabbour, MD.



Related Videos

Lymphoma

Laurie Sehn, MD, on Radiotherapy in Limited-Stage Diffuse Large B-Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, “R-CHOP With or Without Radiotherapy...

Leukemia

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,

Leukemia
Myelodysplastic Syndromes

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinic...

Myelodysplastic Syndromes

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...

Hematologic Malignancies

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementatio...

Advertisement

Advertisement



Advertisement